Overview

Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Positive Advanced Colorectal Cancer

Status:
Not yet recruiting

Trial end date:
2024-03-30

Target enrollment:

Participant gender:

Summary

This phase I study tests the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with CEA positive colorectal cancer that has spread to other places in the body (advanced). Ac225-DOTA-M5A is a humanized monoclonal anti-CEA antibody, linked to a radioactive agent called actinium 225. M5A attaches to CEA positive cancer cells in a targeted way and delivers actinium 225 to kill them.

Phase:

Phase 1

Details

Lead Sponsor:

City of Hope Medical Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins